mProX™ Human ABCG2 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Transporter Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryBased on this stable cell line, we also provide cell-based in vitro assays to evaluate the effects of your compounds or antibodies.
Product Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
Ashley
Verified Customer
Gary
Verified Customer
Any questions about our products? Please visit our frequently asked questions page.
Published Data
Fig.1 Characterization of ABCG2 expression and activity in NSCLC cell lines.
50μg of proteins were put into lysed cells in order to evaluate ABCG2 protein expression using western blot analysis. The information comes from a typical experiment. Three repetitions of each experiment produced findings that were comparable.
Ref: Galetti, Maricla, et al. "Effect of ABCG2/BCRP expression on efflux and uptake of gefitinib in NSCLC cell lines." PloS one 10.11 (2015): e0141795.
Pubmed: 26536031
DOI: 10.1371/journal.pone.0141795
Research Highlights
A constitutively expressed ATP-binding cassette (ABC) transporter, ABCG2 shields a variety of organs from outside substances. Its action impacts the pharmacokinetics of widely used medications and restricts the penetration of treatments into cancerous cells, hence fostering multidrug resistance.
Taylor, Nicholas MI, et al. "Structure of the human multidrug transporter ABCG2." Nature 546.7659 (2017): 504-509.
Pubmed:
28554189
DOI:
10.1038/nature22345
It is acknowledged that ABCG2 plays a significant role in determining the pharmacokinetic properties of the medicines that it substrates. An adequate modification of ABCG2 function during chemotherapy should logically boost the efficacy of anti-cancer medicines by overcoming the MDR phenotype and/or increasing their pharmacokinetics, even though the therapeutic implications of reversing the ABCG2-mediated MDR has proved unconvincing.
Toyoda, Yu, Tappei Takada, and Hiroshi Suzuki. "Inhibitors of human ABCG2: from technical background to recent updates with clinical implications." Frontiers in pharmacology 10 (2019): 208.
Pubmed:
30890942
DOI:
10.3389/fphar.2019.00208